[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stroke-recurrence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stroke-recurrence":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,74,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100638674","cerebral-small-vessel-disease-progression-dependent-on-stroke-type-100638674",false,"NCT07611136","Cerebral Small Vessel Disease Progression Dependent on Stroke Type","Biomarker-based Assessment of Cerebral Small Vessel Disease Progression After Lacunar and Territorial Stroke - a Prospective Cohort Study","ZMA_BIO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Evidence of cerebral small vessel disease on brain MRI, defined as white matter hyperintensities (Fazekas grade 1-3)\n* Assignment to one of the following study groups based on MRI findings:\n* cerebral small vessel disease without evidence of an acute ischemic stroke\n* cerebral small vessel disease with acute lacunar ischemic stroke\n* cerebral small vessel disease with acute territorial ischemic stroke\n* Ability to provide written informed consent\n* Sufficient German language skills to understand study procedures and assessments\n\nExclusion Criteria:\n\n* Alternative plausible causes of white matter hyperintensities other than cerebral small vessel disease (e.g. inflammatory central nervous system disorders, leukodystrophies, brain tumors)\n* Known neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, other dementias)\n* Acute or recent traumatic brain injury\n* Contraindications to magnetic resonance imaging\n* Pregnancy or breastfeeding\n* Life expectancy of less than one year\n* Inability to comply with study procedures or follow-up visits","ALL","18 Years",{"count":20,"type":21},180,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this prospective, observational study is to understand if cerebral small vessel disease (CSVD) has different velocities and patterns of temporal development, dependent on a concurrent ischemic stroke. It focusses on adult patients with known or newly diagnosed CSVD on magnetic resonance imaging. The study will evaluate if blood based, in parts central nervous system specific protein markers, so called biomarkers, have an additional value reflecting the course of CSVD as defined per MRI assessments. Further patient-relevant endpoints include neuropsychological abilities, neurological functional outcomes, quality of life assessments, stroke recurrence risk.",[26,27,28,29],"Cerebral Small Vessel Disease","Stroke","Stroke Recurrence","Biomarkers",[31,32,33],"cerebral small vessel disease","biomarkers","magnetic resonance imaging","RECRUITING","2026-05-20",{"date":37,"type":38},"2026-05-28","ACTUAL",{"date":40,"type":38},"2026-03-26",{"date":42,"type":21},"2028-04-01",{"name":44,"class":45},"Johannes Dorst","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100631395","nora-home-an-ambulatory-multimodal-monitoring-model-in-patients-with-minor-stroke-and-transient-ischemic-attacks-100631395","NCT07500116","NORA-HOME: An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic Attacks","NORA-HOME. Efficiency And Safety An Ambulatory Multimodal Monitoring Model In Patients With Minor Stroke And Transient Ischemic Attacks","NORAHOME","Inclusion Criteria: Patients presenting to the Emergency Department with symptoms of TIA (complete recovery of neurological deficits within \\\u003C24 hours) or minor stroke (NIHSS ≤ 5)\n\n* Age \\>18 years.\n* Availability of a smartphone for the patient or caregiver.\n* Family support and\u002For formal caregiver.\n* Clinical stability during the last 12 hours in the Emergency Department.\n* Signed informed consent by the patient and\u002For family member or legal representative.\n\nExclusion Criteria:\n\n* Severe stenosis or symptomatic arterial occlusion requiring admission for potential reperfusion and\u002For arterial revascularization treatments.\n* Patients with pre-existing neurological or psychiatric conditions that may interfere with or complicate follow-up and evaluations.\n* Clinical (terminal condition) or social (language barrier) impossibility to complete follow-up assessments.",{"count":56,"type":21},250,"INTERVENTIONAL",[59],"NA","In this project, we aim to validate a Home Hospitalization plan for patients with TIA or minor stroke. Our hypothesis is that our Multimodal Home Hospitalization program (NORAHOME) for patients with TIA and minor stroke is safe, reduces the complications associated with conventional hospitalization, and is more efficient than Standard Clinical Practice. To conduct the study, we require the voluntary participation of patients with TIA and minor strokes.",[62,28],"Stroke (CVA) or TIA",[64],"Stroke, TIA, Hospitalization at Home, Stroke Care, PROMs, PREMs","2026-03-25",{"date":67,"type":38},"2026-03-30",{"date":69,"type":38},"2025-01-29",{"date":71,"type":21},"2027-06-29",{"name":73,"class":45},"Hospital Universitari Vall d'Hebron Research Institute",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":57,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":46},"100602194","mobile-health-dietary-intervention-for-stroke-survivors-with-prediabetes-or-type-2-diabetes-100602194","NCT07120334","Mobile Health Dietary Intervention for Stroke Survivors With Prediabetes or Type 2 Diabetes","mHealth Dietary Intervention for Stroke Survivors With Prediabetes or T2D","Inclusion Criteria:\n\n* Aged 30 to 65 years\n* Recent stroke (ischemic, hemorrhagic or Transient Ischemic Attack), within 1-14 days prior to enrollment\n* Confirmed diagnosis of prediabetes or type 2 diabetes, based on HbA1c results\n* Medically stable and cleared for oral diet and physical activity by the attending physician\n* Cleared for thin liquids and regular textures by physician\n* Capable of providing informed consent\n* Able to speak and read English\n* Owns a smartphone OR is willing to use a study-provided iPhone\n* Has sufficient cognitive and physical function to use a mobile app\n* Willing to participate in all study procedures and available for the 12-week duration\n\nExclusion Criteria:\n\n* Severe dysphagia that prevents oral intake\n* Type 1 diabetes\n* Cognitive impairment (e.g., dementia, post-stroke confusion) that precludes consent or compliance, as judged by the clinical care team\n* Current participation in another interventional clinical trial\n* Pregnant or breastfeeding, or planning to become pregnant during the study period\n* Unwilling or unable to provide written informed consent\n* Serious comorbid conditions that, in the opinion of the","30 Years","65 Years",{"count":84,"type":21},40,[59],"Objectives: This study aims to test whether a mobile app called PortionSize Ed can help adults who have had a recent stroke and also have prediabetes or type 2 diabetes improve their diet. Specifically, we want to see if the app can help people follow a Mediterranean-style diet, which may lower the risk of future strokes and improve overall health.\n\nThe main goals are to:\n\n* Test if the app is easy to use and acceptable to participants.\n* See whether the app helps people follow a healthier diet.\n* Look at changes in health indicators like blood sugar, cholesterol, blood pressure, and body fat.\n\nDesign and Outcome:\n\nThis is a randomized controlled pilot study that will involve 40 participants. All participants will be recruited from Queen's Medical Center after a recent stroke and will be randomly assigned to one of two groups:\n\nIntervention Group: Uses the full PortionSize Ed app, gets weekly reminders and educational videos, and has 3 sessions with a registered dietitian (RDN) over 12 weeks.\n\nControl Group: Uses a basic version of the app without feedback or RDN support, and receives usual care for stroke recovery.\n\nAll participants will continue to receive standard care from Queen's, including the My Stroke Recovery Guide. The study lasts 12 weeks, with visits at the beginning and end to collect health data and feedback on the app.\n\nSchedule and Type of Evaluations\u002FInterventions:\n\nParticipants will complete the following:\n\nBaseline and Week 12 Visits: In-person assessments for blood sugar (HbA1c), cholesterol, blood pressure, height, weight, and body composition (using DXA, BIA, and 3D imaging), as well as surveys about their diet and activity levels.\n\nIntervention Group Only:\n\n* Three virtual counseling sessions with a registered dietitian (Week 1, 6, 12)\n* Weekly nutrition goal tracking and texting with the dietitian\n* Watching short educational videos through the app\n* Receiving app-based feedback on how well their diet follows Mediterranean Diet recommendations\n\nDuration of Study: The study will last 12 weeks for each participant, with an optional long-term follow-up using medical records.\n\nSample Size and Population: The study will include 40 adults, ages 30 to 65, who:\n\n* Recently experienced a stroke\n* Have a history of prediabetes or type 2 diabetes\n* Are medically stable and able to use a smartphone (or willing to use a study-provided iPhone)\n* People will be excluded if they have severe swallowing issues, cognitive problems, or dietary needs that would make it hard to follow a Mediterranean-style diet.",[28,88,89],"Type 2 Diabetes","Prediabetes",[91,27,92,89,88,93,94,95,96],"PortionSize Ed","Diabetes","T2D","Mediterranean Diet","mHealth","Hawaii","2026-01-20",{"date":99,"type":38},"2026-01-21",{"date":101,"type":21},"2026-02-01",{"date":103,"type":21},"2026-12-31",{"name":105,"class":45},"University of Hawaii",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":57,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":46},"100606350","phase-3-cilostazol-for-prevention-of-recurrent-stroke-trial-100606350","NCT07174414","Cilostazol for Prevention of Recurrent Stroke Trial","Clarity","Inclusion Criteria:\n\n* Diagnosis of stroke or mini-stroke (also called TIA) within the last 180 days\n* Currently taking aspirin or clopidogrel (not both) to prevent another stroke\n\nExclusion Criteria:\n\n* Had a spontaneous brain bleed within the last 2 years.\n* Moderate to severe heart failure.\n* Life expectancy is less than 6 months.","40 Years",{"count":115,"type":21},2000,[117],"PHASE3","The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.",[28,120,121,122,123,124,125],"Myocardial Infarction","Vascular Death","Ischemic Stroke","TIA (Transient Ischemic Attack)","Stroke (CVA) or Transient Ischemic Attack","Recurrent Stroke","NOT_YET_RECRUITING","2025-09-12",{"date":129,"type":38},"2025-09-16",{"date":131,"type":21},"2026-08",{"date":133,"type":21},"2031-07",{"name":135,"class":45},"Stanford University"]